Development of anti-inflammatory nanodrug for endometriosis treatment
Development of anti-inflammatory nanodrug for endometriosis treatment
批准号:
10709492
负责人:
Jae-Wook Jeong
金额:
$62.86万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-09-30 至 2027-06-30
关键词:
AffectAgeAlbuminsAnimal ModelAnimalsAnti-Inflammatory AgentsAntioxidantsContrast MediaDevelopmentDiagnosisDiseaseElementsEndometrialEnzymesEstrogensExcisionExtravasationFetal DevelopmentFluorescent DyesFunctional disorderGoalsGrowthHormonalHormonesHumanImmunosuppressionIncidenceIndocyanine GreenInfertilityInflammationInflammatoryInjectionsLesionMacrophageMediatingMedicalMedicineMenstrual cycleModelingMolecularMultimodal ImagingNon-Steroidal Anti-Inflammatory AgentsOperative Surgical ProceduresOpticsPainPermeabilityPeroxidasesPharmaceutical PreparationsPhenotypePhosphorylationPlayPregnancyProcessProteinsRecurrent diseaseReportingRiskRoleSignal TransductionStat3 proteinTherapeuticTherapeutic EffectTissuesToxic effectWomanangiogenesiscatalasecerium oxide nanoparticlechronic pelvic painendometriosisendometriosis-related infertilityeutopic endometriumfertility improvementhigh riskhuman tissueimage guidedimmunoregulationimplantationimprovedin vivo imaginginhibitorinnovationinsightmineralizationmouse modelnanonanodrugnanoparticlenanosizednovelnovel strategiesoverexpressionpain reductionpain reliefpain symptomphotoacoustic imagingpre-clinicalreal time monitoringreduce symptomsrelapse riskreproductiveside effecttargeted deliverytargeted treatmenttheranosticstherapeutic evaluationtool
中文摘要
项目总结
英文摘要
Project Summary
Endometriosis affects 10-15% of women of reproductive age, and the incidence increases to 50-60% in women
with chronic pelvic pain and infertility. The current treatments include surgical removal of lesions or hormonal
suppression; however, these may have many side effects and high risks of relapse. Precision-targeted therapy
with a non-hormonal drug can successfully eradicate endometriosis lesions and alleviate pain symptoms while
reducing its off-target toxicity. pSTAT3 signaling plays a crucial role in immunosuppression and inflammation in
endometriosis. A potential therapeutic approach then is to downregulate the endometriosis-specific
inflammation using antioxidant drugs. Cerium oxide nanoparticles (nanoceria) are potent STAT3 inhibitors due
to their anti-inflammatory and immunomodulatory effects. The small-sized nanoceria can accumulate in
endometriotic lesions by extravasation through permeable, angiogenic endometrial vasculature. Our
preliminary results demonstrated pSTAT3 overexpression leads to estrogen-dependent inflammation in
endometriosis, and our ROS scavenging nanoceria remarkably reduces the number of endometriotic lesions in
a mouse model. The nanodrug (nanoceria), coated with albumin protein and conjugated with NIR fluorescent
dye (indocyanine green), shows successful systemic endometrial tissue targeting under photoacoustic image
guidance. We hypothesize the novel nanodrug (albumin-nanoceria-ICG) will significantly suppress
endometriotic lesion growth and result in reduced pain and infertility. Multimodal imaging simultaneously offers
real-time monitoring of endometriosis progression and pregnancy and fetal development in living animals. Aim
1 will investigate how pSTAT3 in endometriosis contributes to inflammatory and immunosuppressive conditions
using our endometriosis mouse model and in vivo imaging. Aim 2 will evaluate the theranostic potential of
nanoceria on endometriosis progression and pain alleviation. Aim 3 examines whether the nanodrug will
improve fertility, endometrial receptivity, and implantation. The proposed studies will support uncovering the
molecular mechanism of inflammation in endometriosis and lead to non-surgical and non-hormonal treatment.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
The role of cholesterol biosynthesis in metastatic and recurrent endometrialcancer
-
批准号:10560609
-
项目类别:
-
资助金额:$54.09万
-
财政年份:2022
-
负责人:Jae-Wook Jeong
-
依托单位:
Molecular mechanisms of endometrial progesterone resistance
-
批准号:10618181
-
项目类别:
-
资助金额:$51.47万
-
财政年份:2022
-
负责人:Jae-Wook Jeong
-
依托单位:
The role of cholesterol biosynthesis in metastatic and recurrent endometrial cancer
-
批准号:10467152
-
项目类别:
-
资助金额:$25.49万
-
财政年份:2022
-
负责人:Jae-Wook Jeong
-
依托单位:
The role of cholesterol biosynthesis in metastatic and recurrent endometrialcancer
-
批准号:10661912
-
项目类别:
-
资助金额:$32.92万
-
财政年份:2022
-
负责人:Jae-Wook Jeong
-
依托单位:
Epigenetic regulation of receptive endometrium
-
批准号:10674101
-
项目类别:
-
资助金额:$43.0万
-
财政年份:2022
-
负责人:Jae-Wook Jeong
-
依托单位:
Epigenetic regulation of receptive endometrium
-
批准号:10551346
-
项目类别:
-
资助金额:$58.72万
-
财政年份:2022
-
负责人:Jae-Wook Jeong
-
依托单位:
Molecular mechanisms of endometrial progesterone resistance
-
批准号:10662676
-
项目类别:
-
资助金额:$46.95万
-
财政年份:2022
-
负责人:Jae-Wook Jeong
-
依托单位:
Epigenetic regulation of receptive endometrium
-
批准号:10390408
-
项目类别:
-
资助金额:$16.12万
-
财政年份:2021
-
负责人:Jae-Wook Jeong
-
依托单位:
SIRT1 as a Therapeutic Target in Endometriosis
-
批准号:10309093
-
项目类别:
-
资助金额:$38.58万
-
财政年份:2021
-
负责人:Jae-Wook Jeong
-
依托单位:
Epigenetic regulation of receptive endometrium
-
批准号:10231662
-
项目类别:
-
资助金额:$60.68万
-
财政年份:2021
-
负责人:Jae-Wook Jeong
-
依托单位:
SIRT1 as a Therapeutic Target in Endometriosis
-
批准号:10700024
-
项目类别:
-
资助金额:$42.47万
-
财政年份:2021
-
负责人:Jae-Wook Jeong
-
依托单位:
SIRT1 as a Therapeutic Target in Endometriosis
-
批准号:10474480
-
项目类别:
-
资助金额:$35.83万
-
财政年份:2021
-
负责人:Jae-Wook Jeong
-
依托单位:
Molecular mechanisms of endometrial progesterone resistance
-
批准号:10393011
-
项目类别:
-
资助金额:$4.52万
-
财政年份:2020
-
负责人:Jae-Wook Jeong
-
依托单位:
Molecular mechanisms of endometrial progesterone resistance
-
批准号:10229616
-
项目类别:
-
资助金额:$51.47万
-
财政年份:2020
-
负责人:Jae-Wook Jeong
-
依托单位:
Risk factors for early pregnancy loss
-
批准号:9111405
-
项目类别:
-
资助金额:$32.08万
-
财政年份:2016
-
负责人:Jae-Wook Jeong
-
依托单位:
Risk factors for early pregnancy loss
-
批准号:9257438
-
项目类别:
-
资助金额:$32.16万
-
财政年份:2016
-
负责人:Jae-Wook Jeong
-
依托单位:
Steroid Hormone Regulation of Uterine Function and Dysfunction
-
批准号:8097062
-
项目类别:
-
资助金额:$3.28万
-
财政年份:2010
-
负责人:Jae-Wook Jeong
-
依托单位:
Steroid Hormone Regulation of Uterine Function and Dysfunction
-
批准号:7609077
-
项目类别:
-
资助金额:$26.1万
-
财政年份:2008
-
负责人:Jae-Wook Jeong
-
依托单位:
Steroid Hormone Regulation of Uterine Function and Dysfunction
-
批准号:8059736
-
项目类别:
-
资助金额:$24.8万
-
财政年份:2008
-
负责人:Jae-Wook Jeong
-
依托单位:
Steroid Hormone Regulation of Uterine Function and Dysfunction
-
批准号:8249345
-
项目类别:
-
资助金额:$24.8万
-
财政年份:2008
-
负责人:Jae-Wook Jeong
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: